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Background
In some forms of arterial hypertension and as one of the
earliest and pathognomonic events in cardiac hypertro-
phy and insufficiency, the cardiac synthesis and release of
ANP and BNP is markedly enhanced, but the GC-A-medi-
ated effects of the NPs are clearly diminished, indicating a
receptor or postreceptor defect of GC-A. Thus, from a
pathophysiological perspective, identifying the specific
mechanisms involved in the downregulation of GC-A
activity has important implications. Biochemical studies
in transfected GC-A-overexpressing cells showed that
phosphorylation of GC-A is essential for its activation
process. In turn, inactivation of GC-A probably involves
dephosphorylation [1]. NP-dependent activation of GC-A
can be reduced not only by chronic exposure to NPs
(homologous desensitization) but also by exposure to
agents other than NPs (heterologous desensitization). It
has been shown in cell culture systems that Angiotensin II
and endothelin decrease the responsiveness of GC-A. This
is probably mediated by a protein kinase C-induced
dephosphorylation of GC-A. However, ultimately the pre-
cise posttranslational modifications leading to homolo-
gous vs. heterologous GC-A desensitization have not been
fully characterized. The present study describes the func-
tional characterization of an epitope-tagged GC-A recep-
tor which might help to enrich the receptor for the
characterization of putative posttranslational modifica-
tions.
Methods, results and conclusion
The FLAG (DYKDDDDK) epitope was positioned imme-
diately after the cleavage site of the signal peptide by PCR-
mediated mutagenesis (pCMV5-FLAG-GC-A) [2]. HEK
cells were transfected with cDNAs for GC-A or GC-A
tagged with the FLAG epitope.
To determine cellular cGMP responses, transfected cells
on 24-well plates were pretreated with 0.1 mM 3-isobutyl-
1-methylxanthine for 15 min and then stimulated with
ANP during additional 10 min. Ethanol (70%, v/v) was
used to terminate the reaction. Cyclic GMP in the cell
extracts was quantitated by radioimmunoassay. ANP (1
pM – 100 nM) elicited concentration-dependent increases
in cellular cGMP which were nearly identical in GC-A –
and FLAG-GC-A – transfected HEK cells. Pretreatment of
the cells with the protein kinase C activator PMA (200 nM,
30 min) dramatically reduced these responses.
Additionally, fluorescence resonance energy transfer
(FRET) with a new sensor for cGMP [3] was used to mon-
itor the temporal and spatial resolution of cGMP eleva-
tions. Both, the kinetics, duration and extent of cGMP
formation in response to ANP were similar in GC-A and
FLAG-GC-A – transfected HEK cells.
We conclude that addition of the FLAG-epitope does not
interfere with the ability of the receptor to bind or be acti-
vated by ANP. In future studies we will apply this tool to
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enrich the protein by immunoprecipitation and character-
ize putative modifications by mass spectrometry.
Acknowledgements
Supported by Deutsche Forschungsgemeinschaft (SFB 487).
References
1. Potter LR: Domain analysis of human transmembrane guany-
lyl cyclase receptors: implications for regulation.  Front Biosci
2005, 10:1205-1220.
2. Chinkers M, Wilson EM: Ligand-independent oligomerization
of natriuretic peptide receptors. Identification of hetero-
meric receptors and a dominant negative mutant.  J Biol Chem
1992, 267:18589-18597.
3. Nikolaev VO, Gambaryan S, Lohse MJ: Fluorescent sensors for
rapid monitoring of intracellular cGMP.  Nat Methods 2006,
3:11-12.Page 2 of 2
(page number not for citation purposes)
